CorMedix (CRMD) Research & Development (2016 - 2025)
CorMedix (CRMD) has disclosed Research & Development for 13 consecutive years, with $8.6 million as the latest value for Q4 2025.
- Quarterly Research & Development rose 398.14% to $8.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $19.3 million through Dec 2025, up 390.44% year-over-year, with the annual reading at $19.3 million for FY2025, 390.44% up from the prior year.
- Research & Development hit $8.6 million in Q4 2025 for CorMedix, up from $5.1 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $8.6 million in Q4 2025 to a low of $650988.0 in Q2 2024.
- Historically, Research & Development has averaged $3.1 million across 5 years, with a median of $2.7 million in 2023.
- Biggest five-year swings in Research & Development: crashed 86.42% in 2024 and later skyrocketed 601.07% in 2025.
- Year by year, Research & Development stood at $3.2 million in 2021, then dropped by 12.12% to $2.8 million in 2022, then fell by 6.3% to $2.7 million in 2023, then tumbled by 35.19% to $1.7 million in 2024, then surged by 398.14% to $8.6 million in 2025.
- Business Quant data shows Research & Development for CRMD at $8.6 million in Q4 2025, $5.1 million in Q3 2025, and $2.4 million in Q2 2025.